Vyvanse (generic name: lisdexamfetamine dimesylate) is a central nervous system (CNS) stimulant drug. It is FDA approved to treat:
Vyvanse is manufactured by Shire, the same pharmaceutical company that makes Adderall XR. It comes in chewable tablets or capsules ranging from 10 mg to 70 mg doses. It is the brand name for lisdexamfetamine dimesylate.
The National Survey on Drug Use and Health lists Vyvanse in the same group as other amphetamine-based drugs. However, it doesn’t actually contain an active amphetamine. Lisdexamfetamine is a prodrug — meaning that it is inactive until the body metabolizes it.
Vyvanse is only effective if ingested. Therefore, it cannot be injected or snorted. Shire stated in their advertisements that it had a lower abuse liability than it’s active amphetamine-based competitors. However, the Department of Justice found these claims, and others the company made about their drugs, false and fined Shire 56.5 million dollars.
Because the body must metabolize it first, Vyvanse takes longer than Adderall and other amphetamine-based drugs to take effect. Effects typically last 10 to 12 hours, while some studies report up to 14 hours. Prescribed doses range from 20 mg to 70 mg.
Vyvanse stimulates your central nervous system and produces several effects, including increased:
These effects are usually safe, and often beneficial, for individuals with ADHD or binge-eating disorder.
Recreational users (people without ADHD or binge-eating disorder) may experience feelings of euphoria, hyperfocus, and extreme bursts of energy. This is why Vyvanse has a high risk of abuse.
Like virtually all prescription drugs, Vyvanse does come with potential side effects. Common side effects include:
In rare cases, there is a risk of serious side effects like heart attack or stroke with any type of stimulant use. Call your doctor immediately if you or your child experience any symptoms off heart problems including shortness of breath, chest pain, or fainting while taking Vyvanse.
Vyvanse is known to interact with several different types of drugs. If used with monoamine oxidase inhibitors (MAOIs), severe and possibly fatal effects may occur. Serious adverse effects may occur if taken with:
Consult with your doctor to get a full list of drugs known to interact with lisdexamfetamine.
Both Vyvanse and Adderall are central nervous system (CNS) stimulants. The DEA classifies them both as Schedule II drugs, meaning they have a high potential for abuse and addiction.
This chart compares the most relevant aspects of each drug:
|Approved to treat:||
|Duration of effects:||
|Risk of abuse:||
|Methods of abuse:||
The main difference between the two drugs is how the body processes them. Dextroamphetamine, the main active ingredient in Adderall, enters the body in an active state, so the effects are more immediate and intense. Lisdexamfetamine, the active ingredient in Vyvanse, enters the body in an inactive state and gets converted to dextroamphetamine.
As mentioned, Vyvanse is a Schedule II controlled substance due to its high risk of abuse and addiction. Lisdexamfetamine can be habit-forming, so it should always be taken exactly as prescribed by your doctor.
Many students abuse Vyvanse as a “study drug.” They take Vyvanse hoping to gain a competitive advantage by achieving greater levels of focus or by staying up late and “cramming” for a test. Other common study drugs include Adderall, Ritalin, Concerta, and Dexedrine.
Students believe that these “study drugs” will improve their academic performance, however, studies show that students who misuse these drugs actually have lower grades than those who don’t. Prescription drug misuse can lead to a number of serious health risks, including:
In addition, since one of the side effects is appetite suppression, many people misuse Vyvanse in order to lose weight. Recreational users also abuse the drug to get high.
Vyvanse can cause an overdose if someone takes more than the recommended dose. Symptoms of Vyvanse overdose include:
If a Vyvanse overdose isn’t treated quickly by a medical professional, the consequences can be fatal.
Some individuals mix Vyvanse and alcohol in order to drink more, stay up later, or combine highs. Though there has been no research done on the interaction of Vyvanse and alcohol, and there are no warnings in the Food and Drug Administration Vyvanse medication guide, it is not recommended to mix the two.
Alcohol is a central nervous system (CNS) depressant, whereas Vyvanse is a CNS stimulant. The combination of these two drugs can lead to serious heart issues.
Mixing Vyvanse and alcohol can cause mild short term effects, such as dizziness, high blood pressure, and increased heart rate. Severe and life-threatening effects, such as sudden heart attack or stroke, are also possible.
Vyvanse is considered an addictive substance. Individuals with a prescription, or people who abuse it frequently, can also develop a tolerance, meaning they need more and more of the substance to achieve the same effects.
If someone who has become physically or psychologically dependent on Vyvanse stops using it suddenly, they may experience withdrawal symptoms. These symptoms range from mild to severe depending on a number of factors including the length of use, dose, and health of the patient.
There are several symptoms, or warning signs, of Vyvanse addiction, including:
Fortunately, there are several treatment options for anyone suffering from Vyvanse addiction. The most effective treatment options are:
If you or someone you care about is showing signs of Vyvanse abuse or addiction, it’s time for them to get help. Reach out to a professional to review available treatment options.
Find Help For Your Addiction
You don’t have to overcome your addiction alone. Professional guidance and support is available. Begin a life of recovery by reaching out to a specialist today.
Goodman, David W. “Lisdexamfetamine dimesylate (Vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder.” P & T: a peer-reviewed journal for formulary management vol. 35,5 (2010): 273-87., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873712/
Najib, Jadwiga et al. “Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder.” Journal of central nervous system disease vol. 9 1179573517728090. 23 Aug. 2017, doi:10.1177/1179573517728090, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571766/
“Shire Pharmaceuticals LLC to Pay $56.5 Million to Resolve False Claims Act Allegations Relating to Drug Marketing and Promotion Practices.” The United States Department of Justice, 8 Jan. 2016, www.justice.gov/opa/pr/shire-pharmaceuticals-llc-pay-565-million-resolve-false-claims-act-allegations-relating-drug.